Timothee and Prasad talk 2023 cancer trials

Plenary Session

Vinay Prasad, MD MPH

Health, Medicine, Policy, Oncology, Science & Medicine

4.7 • 789 Ratings

🗓️ 24 December 2023

⏱️ 44 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

We talk about 2023 cancer trials

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome back to the plenary session podcast.
0:02.3	I'm joined by my friend and colleague, Dr. Timothy Olivier.
0:05.6	And by the time you're listening to this, he is officially an Agilon, which means an attending physician at the University Hospital, Geneva.
0:13.0	Timothy, it's a pleasure to see you and congratulations on the big promotion.
0:16.8	Hi, I mean, thanks a lot coming from you.
0:19.1	It's really nice and I'm happy to join again a plenary session episode with you today.
0:24.8	The episodes with Timothy Olivier are the most popular by listener request. People say, VP brings the fire and Timothy brings a breath of fresh air.
0:33.6	So that's what we got here. We got fire and fresh air. So let's get started.
0:38.6	Yeah, let's get started. Yeah. Here's the topics for today's discussion. Number one and Fordemab Vedotin and
0:43.0	Pembralizumab in the frontline treatment of metastatic uothelial cancer. Number two, HLA, which is the
0:50.0	human leukocyte antigen and drugs like Tabenta Fusp, which is a fusion protein in melanoma
0:55.5	GP100 fusion protein that only works in uveal melanoma and only works if you're HLA, A2A,
1:05.4	A2.02.2.2. A2.02. And it don't work if you're not. And it turns out that the HLA drug development program
1:15.0	is, as they say in the business, a little bit racist, a little bit racist. We're going to talk
1:20.1	about that. And then what was the third topic we're going to talk about, Timothy?
1:24.1	Maybe we could talk about the ODAC meeting about the Cold Break 200 trial, if you want.
1:28.6	Oh, break 200.
1:29.7	Great, great, great.
1:30.7	Okay, let's start it off.
1:32.4	Evie Pemberlizumab.
1:33.6	Look, it got a standing ovation.
1:36.9	In Fordomab Vidotin, Pembralizumab has an overall survival benefit.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.